ArticleJournal of molecular histology2025
Upregulation of NR4A3 increases sensitivity to niraparib in ovarian cancer cells resistant to this drug.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
Acquired resistance is the major clinical change for patients with ovarian cancer undergoing niraparib (NRP) treatment. Targeting NRP-resistant cells would be NRP offers an effective strategy for reversing resistance and inhibiting disease progression. NR4A3 is known as a tumor suppressor in multiple cancers, but its role in NRP resistance of ovarian cancer is still unclear. NRP-resistant ovarian cancer cell lines (A2780/NRP and OVCAR3/NRP) were established by gradually increasing NRP concentrations. The phenotype of resistant cell lines was characterized using proliferation, colony formation, and migration assays. RNA sequencing was performed to identify genes dysregulated in the resistant cell lines. We also performed gain- and loss-of-function assays to investigate the role of NR4A3 in NRP resistance. The resistance indices for A2780/NRP and OVCAR3/NRP were 8.95 and 4.42, respectively. These resistant cells exhibited slower proliferation and robust colony formation and migration abilities. NR4A3 exhibited the highest average log2 fold change among the candidates. Overexpression of NR4A3 sensitized the NRP-resistant cells and reduced their proliferation, colony formation, and migration capabilities, whereas downregulation of NR4A3 in the parental cells caused opposite results. Downregulation of NR4A3 contributes to NRP resistance, and activation of NR4A3 maybe a promising strategy to reverse NRP resistance.
Indexed as
Identifiers
41026279What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.